aspirin has been researched along with Diabetic Cardiomyopathies in 15 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this analysis, we aimed to compare the efficacy and safety of dual therapy (DT) with a non-vitamin K oral anticoagulant (NOAC) and an adenosine diphosphate receptor antagonist (P2Y12 inhibitor) vs triple therapy (TT) with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus (DM) patients with co-existing atrial fibrillation (AF) following percutaneous coronary intervention (PCI)." | 9.12 | Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneo ( Wang, Q; Yang, K, 2021) |
| "In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction." | 7.83 | Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2016) |
| " Ticagrelor was more effective than clopidogrel in TAPT; however, when using the combination of aspirin, ticagrelor, and tirofiban, close monitoring is required for possible bleeding complications." | 5.24 | Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study. ( Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y, 2017) |
| "Although aspirin has no significant risk on primary endpoints of cardiovascular events and bleeding outcomes in patients with diabetes compared to control, major adverse cardiovascular events (MACE) were significantly lower in the aspirin group." | 5.12 | Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis. ( Gu, Q; Li, X; Ma, H; Niu, H; Wang, R, 2021) |
| "In this analysis, we aimed to compare the efficacy and safety of dual therapy (DT) with a non-vitamin K oral anticoagulant (NOAC) and an adenosine diphosphate receptor antagonist (P2Y12 inhibitor) vs triple therapy (TT) with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus (DM) patients with co-existing atrial fibrillation (AF) following percutaneous coronary intervention (PCI)." | 5.12 | Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneo ( Wang, Q; Yang, K, 2021) |
| "In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction." | 3.83 | Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients. ( Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D, 2016) |
| " Because increased platelet reactivity and/or turnover are postulated mechanisms, we examined whether higher and/or more frequent aspirin dosing might reduce platelet reactivity more effectively." | 2.82 | Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. ( Bethel, MA; Coleman, RL; Harrison, P; Hill, L; Holman, RR; Kennedy, I; Oulhaj, A; Sourij, H; Sun, Y; Tucker, L; White, S, 2016) |
| " There were differences in the effect of aspirin by dosage and treatment duration on overall stroke outcomes (P for interaction for all < 0." | 2.55 | Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. ( Khunti, K; Kunutsor, SK; Seidu, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, H | 1 |
| Gu, Q | 1 |
| Niu, H | 1 |
| Li, X | 1 |
| Wang, R | 1 |
| Giorda, CB | 1 |
| Wang, Q | 1 |
| Yang, K | 1 |
| Liu, Y | 1 |
| Liu, H | 1 |
| Hao, Y | 1 |
| Hao, Z | 1 |
| Geng, G | 1 |
| Han, W | 1 |
| Chen, Q | 1 |
| Wang, D | 1 |
| Liu, L | 1 |
| Jia, K | 1 |
| Zhou, Y | 1 |
| Rosiak, M | 2 |
| Postuła, M | 2 |
| Kapłon-Cieślicka, A | 2 |
| Trzepla, E | 1 |
| Filipiak, KJ | 2 |
| Członkowski, A | 1 |
| Opolski, G | 2 |
| Serafin, A | 1 |
| Kondracka, A | 1 |
| Bethel, MA | 1 |
| Harrison, P | 1 |
| Sourij, H | 1 |
| Sun, Y | 1 |
| Tucker, L | 1 |
| Kennedy, I | 1 |
| White, S | 1 |
| Hill, L | 1 |
| Oulhaj, A | 1 |
| Coleman, RL | 1 |
| Holman, RR | 1 |
| Borghi, C | 1 |
| Omboni, S | 1 |
| Novo, S | 1 |
| Vinereanu, D | 1 |
| Ambrosio, G | 1 |
| Ambrosioni, E | 1 |
| Kunutsor, SK | 1 |
| Seidu, S | 1 |
| Khunti, K | 1 |
| Korkmaz-Icöz, S | 1 |
| Al Said, S | 1 |
| Radovits, T | 1 |
| Li, S | 1 |
| Brune, M | 1 |
| Hegedűs, P | 1 |
| Atmanli, A | 1 |
| Ruppert, M | 1 |
| Brlecic, P | 1 |
| Lehmann, LH | 1 |
| Lahrmann, B | 1 |
| Grabe, N | 1 |
| Yoshikawa, Y | 1 |
| Yasui, H | 1 |
| Most, P | 1 |
| Karck, M | 1 |
| Szabó, G | 1 |
| Faucon, AL | 1 |
| Madjalian, AM | 1 |
| Bobrie, G | 1 |
| Amar, L | 1 |
| Azizi, M | 1 |
| Bhatt, LK | 1 |
| Veeranjaneyulu, A | 1 |
| Kuliczkowski, W | 1 |
| Gąsior, M | 1 |
| Pres, D | 1 |
| Kaczmarski, J | 1 |
| Greif, M | 1 |
| Łaszewska, A | 1 |
| Szewczyk, M | 1 |
| Hawranek, M | 1 |
| Tajstra, M | 1 |
| Żegleń, S | 1 |
| Poloński, L | 1 |
| Serebruany, V | 1 |
| Serebruany, VL | 1 |
| Dinicolantonio, JJ | 1 |
| Can, MM | 1 |
| Goto, S | 1 |
3 reviews available for aspirin and Diabetic Cardiomyopathies
4 trials available for aspirin and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, | 2017 |
The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 2; Di | 2013 |
Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelet Disorders; Blood Platelets; Card | 2013 |
Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Over Studies; Cyclooxygenase Inhibitors; Diabetes Mel | 2016 |
8 other studies available for aspirin and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
[2019 ESC Guidelines on diabetes, pre-diabetes and cardiovascular diseases: what's new? The diabetologist's point of view].
Topics: Anticoagulants; Aspirin; Cardiology; Cholesterol, LDL; Diabetic Cardiomyopathies; Europe; Heart Dise | 2020 |
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Cardiovascular Diseases; Diabeti | 2016 |
Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway.
Topics: Administration, Oral; Animals; Aspirin; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; | 2016 |
[Towards new targets in the treatment of hypertension?]
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2016 |
A therapeutic approach to treat cardiovascular dysfunction of diabetes.
Topics: Animals; Aspirin; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Cardiomyo | 2012 |
Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Glucose; Clopidogrel; Diabetic Cardiomyopathies; Elec | 2012 |
Tighter aspirin control urged for patients with diabetes. Taking aspirin increases bleeding risk that is not always outweighed by the potential benefits for patients with low cardiovascular disease risk.
Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Dose-Response Relationship, Drug; Gas | 2010 |
Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel.
Topics: Aged; Aspirin; Brain Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Clopidogrel; Colonic | 2013 |